Atea Pharmaceuticals
AVIR
106 hedge funds and large institutions have $189M invested in Atea Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 16 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less capital invested
Capital invested by funds: $194M → $189M (-$5.35M)
2% less funds holding
Funds holding: 108 → 106 (-2)
1.9% less ownership
Funds ownership: 68.6% → 66.7% (-1.9%)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
55% less call options, than puts
Call options by funds: $115K | Put options by funds: $255K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$3.18M |
| 2 |
JP Morgan Chase
New York
|
+$1.04M |
| 3 |
NM
Newtyn Management
New York
|
+$665K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$611K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$604K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$6.98M |
| 2 |
AC
Almitas Capital
Santa Monica,
California
|
-$2.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.25M |
| 4 |
AI
Acuitas Investments
Seattle,
Washington
|
-$1.08M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$642K |
AVIR Hedge Fund Activity: Q4 2024 in Review
106 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q4 2024, worth a combined $189M — down 2.8% from $194M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AVIR and 14 opened new positions — a net loss of 2 holders — while 32 trimmed existing stakes and 38 added.
The largest buyer was BML Capital Management, adding an estimated $3.18M. The largest seller was EcoR1 Capital, cutting an estimated $6.98M.
- 106 institutional investors held Atea Pharmaceuticals (AVIR) as of Q4 2024, down from 108 in Q3 2024.
- Funds reported $189M of Atea Pharmaceuticals stock for Q4 2024, down 2.8% quarter-over-quarter.
- 14 funds opened new Atea Pharmaceuticals positions in Q4 2024 and 16 closed out, a net change of -2 holders.
- The largest Atea Pharmaceuticals buyer in Q4 2024 was BML Capital Management, an estimated $3.18M added.
- The largest Atea Pharmaceuticals seller in Q4 2024 was EcoR1 Capital, an estimated $6.98M sold.
Based on aggregated 13F filings for Q4 2024.